Pular para o conteúdo principal
Ranking Invest

NRIX - Nurix Therapeutics, Inc.

Segmento: HealthcareNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Análise Ranking Invest

Valuation estimado
-$ 387.39 Mi
Valor de Mercado
$ 2.61 Bi
Desconto (AV)-772.7%
IVR
-0.15A companhia vale -0,15 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.31O valuation alternativo equivale a -31% do valor de mercado da companhia.
MLL
-0.31O lucro líquido dos controladores em 16 trimestres equivale a -31% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 402.63 Mi

Dívida Líquida

-$ 67.69 Mi

L4T

-$ 341.35 Mi

MM4T

-1013.83%

Indicadores Básicos

ROE

-84.78%

Índices de Previsibilidade

Receita Líquida

E0.29

Lucro

B0.19

Margem

D0.62

Índices de Tendência

Receita Líquida

E-3.70

Lucro

G-10.00

Margem

F-7.04

Índices de Endividamento

DIV/PAT

-0.17

DIV/L4T

0.20

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.